News
-
-
-
PRESS RELEASE
Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 biosimilar candidate to Stelara. Approval expected in early Q4 2024. Biosimilars boost healthcare access & reduce costs globally -
PRESS RELEASE
Attestation personne responsable
-
PRESS RELEASE
Rapport des CAC
-
PRESS RELEASE
Rapport financier semestriel
-
-
-
-